PortalPublikationenLong-term Follow-up and Patterns of Recurrence of Patients W...

Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT

Standard

Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. / Hörner-Rieber, Juliane; Bernhardt, Denise; Blanck, Oliver; Duma, Marciana; Eich, Hans Th; Gerum, Sabine; Gkika, Eleni; Hass, Peter; Henkenberens, Christoph; Herold, Hans-Ulrich; Hildebrandt, Guido; Imhoff, Detlef; Kahl, Henning; Janssen, Stefan; Jurianz, Katrin; Krempien, Robert; Lautenschläger, Stefan Friedrich; Lohaus, Fabian; Mueller, Arndt-Christian; Petersen, Cordula; Sackerer, Irina; Scafa, Davide; Schrade, Elsge; Uhlmann, Lorenz; Wittig, Andrea; Guckenberger, Matthias.

in: CLIN LUNG CANCER, Jahrgang 20, Nr. 6, 11.2019, S. e667-e677.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hörner-Rieber, J, Bernhardt, D, Blanck, O, Duma, M, Eich, HT, Gerum, S, Gkika, E, Hass, P, Henkenberens, C, Herold, H-U, Hildebrandt, G, Imhoff, D, Kahl, H, Janssen, S, Jurianz, K, Krempien, R, Lautenschläger, SF, Lohaus, F, Mueller, A-C, Petersen, C, Sackerer, I, Scafa, D, Schrade, E, Uhlmann, L, Wittig, A & Guckenberger, M 2019, 'Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT', CLIN LUNG CANCER, Jg. 20, Nr. 6, S. e667-e677. https://doi.org/10.1016/j.cllc.2019.06.024

APA

Hörner-Rieber, J., Bernhardt, D., Blanck, O., Duma, M., Eich, H. T., Gerum, S., Gkika, E., Hass, P., Henkenberens, C., Herold, H-U., Hildebrandt, G., Imhoff, D., Kahl, H., Janssen, S., Jurianz, K., Krempien, R., Lautenschläger, S. F., Lohaus, F., Mueller, A-C., ... Guckenberger, M. (2019). Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. CLIN LUNG CANCER, 20(6), e667-e677. https://doi.org/10.1016/j.cllc.2019.06.024

Vancouver

Hörner-Rieber J, Bernhardt D, Blanck O, Duma M, Eich HT, Gerum S et al. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. CLIN LUNG CANCER. 2019 Nov;20(6):e667-e677. https://doi.org/10.1016/j.cllc.2019.06.024

Bibtex

@article{5cd62600a45a4492b84e999c24f14275,
title = "Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT",
abstract = "INTRODUCTION: This multicenter study aims to analyze outcome as well as early versus late patterns of recurrence following pulmonary stereotactic body radiotherapy (SBRT) for patients with oligometastatic non-small-cell lung cancer (NSCLC).MATERIALS AND METHODS: This analysis included 301 patients with oligometastatic NSCLC treated with SBRT for 336 lung metastases. Although treatment of the primary tumor consisted of surgical resection, radiochemotherapy, and/or systemic therapy, pulmonary oligometastases were treated with SBRT.RESULTS: The median follow-up time was 16.1 months, resulting in 2-year overall survival (OS), local control (LC), and distant control (DC) of 62.2%, 82.0%, and 45.2%, respectively. Multivariate analysis identified age (P = .019) and histologic subtype (P = .028), as well as number of metastatic organs (P < .001) as independent prognostic factors for OS. LC was superior for patients with favorable histologic subtype (P = .046) and SBRT with a higher biological effective dose at isocenter (P = .037), whereas DC was inferior for patients with metastases in multiple organs (P < .001) and female gender (P = .027). Early (within 24 months) local or distant progression was observed in 15.3% and 36.5% of the patients. After 24 months, the risk of late local failure was low, with 3- and 4-year local failure rates of only 4.0%, and 7.6%. In contrast, patients remained at a high risk of distant progression with 3- and 4-year failure rates of 13.3% and 24.1%, respectively, with no plateau observed.CONCLUSION: SBRT for pulmonary oligometastatic NSCLC resulted in favorable LC and promising OS. The dominant failure pattern is distant with a continuously high risk of disease progression for many years.",
author = "Juliane H{\"o}rner-Rieber and Denise Bernhardt and Oliver Blanck and Marciana Duma and Eich, {Hans Th} and Sabine Gerum and Eleni Gkika and Peter Hass and Christoph Henkenberens and Hans-Ulrich Herold and Guido Hildebrandt and Detlef Imhoff and Henning Kahl and Stefan Janssen and Katrin Jurianz and Robert Krempien and Lautenschl{\"a}ger, {Stefan Friedrich} and Fabian Lohaus and Arndt-Christian Mueller and Cordula Petersen and Irina Sackerer and Davide Scafa and Elsge Schrade and Lorenz Uhlmann and Andrea Wittig and Matthias Guckenberger",
note = "Copyright {\textcopyright} 2019 Elsevier Inc. All rights reserved.",
year = "2019",
month = nov,
doi = "10.1016/j.cllc.2019.06.024",
language = "English",
volume = "20",
pages = "e667--e677",
journal = "CLIN LUNG CANCER",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT

AU - Hörner-Rieber, Juliane

AU - Bernhardt, Denise

AU - Blanck, Oliver

AU - Duma, Marciana

AU - Eich, Hans Th

AU - Gerum, Sabine

AU - Gkika, Eleni

AU - Hass, Peter

AU - Henkenberens, Christoph

AU - Herold, Hans-Ulrich

AU - Hildebrandt, Guido

AU - Imhoff, Detlef

AU - Kahl, Henning

AU - Janssen, Stefan

AU - Jurianz, Katrin

AU - Krempien, Robert

AU - Lautenschläger, Stefan Friedrich

AU - Lohaus, Fabian

AU - Mueller, Arndt-Christian

AU - Petersen, Cordula

AU - Sackerer, Irina

AU - Scafa, Davide

AU - Schrade, Elsge

AU - Uhlmann, Lorenz

AU - Wittig, Andrea

AU - Guckenberger, Matthias

N1 - Copyright © 2019 Elsevier Inc. All rights reserved.

PY - 2019/11

Y1 - 2019/11

N2 - INTRODUCTION: This multicenter study aims to analyze outcome as well as early versus late patterns of recurrence following pulmonary stereotactic body radiotherapy (SBRT) for patients with oligometastatic non-small-cell lung cancer (NSCLC).MATERIALS AND METHODS: This analysis included 301 patients with oligometastatic NSCLC treated with SBRT for 336 lung metastases. Although treatment of the primary tumor consisted of surgical resection, radiochemotherapy, and/or systemic therapy, pulmonary oligometastases were treated with SBRT.RESULTS: The median follow-up time was 16.1 months, resulting in 2-year overall survival (OS), local control (LC), and distant control (DC) of 62.2%, 82.0%, and 45.2%, respectively. Multivariate analysis identified age (P = .019) and histologic subtype (P = .028), as well as number of metastatic organs (P < .001) as independent prognostic factors for OS. LC was superior for patients with favorable histologic subtype (P = .046) and SBRT with a higher biological effective dose at isocenter (P = .037), whereas DC was inferior for patients with metastases in multiple organs (P < .001) and female gender (P = .027). Early (within 24 months) local or distant progression was observed in 15.3% and 36.5% of the patients. After 24 months, the risk of late local failure was low, with 3- and 4-year local failure rates of only 4.0%, and 7.6%. In contrast, patients remained at a high risk of distant progression with 3- and 4-year failure rates of 13.3% and 24.1%, respectively, with no plateau observed.CONCLUSION: SBRT for pulmonary oligometastatic NSCLC resulted in favorable LC and promising OS. The dominant failure pattern is distant with a continuously high risk of disease progression for many years.

AB - INTRODUCTION: This multicenter study aims to analyze outcome as well as early versus late patterns of recurrence following pulmonary stereotactic body radiotherapy (SBRT) for patients with oligometastatic non-small-cell lung cancer (NSCLC).MATERIALS AND METHODS: This analysis included 301 patients with oligometastatic NSCLC treated with SBRT for 336 lung metastases. Although treatment of the primary tumor consisted of surgical resection, radiochemotherapy, and/or systemic therapy, pulmonary oligometastases were treated with SBRT.RESULTS: The median follow-up time was 16.1 months, resulting in 2-year overall survival (OS), local control (LC), and distant control (DC) of 62.2%, 82.0%, and 45.2%, respectively. Multivariate analysis identified age (P = .019) and histologic subtype (P = .028), as well as number of metastatic organs (P < .001) as independent prognostic factors for OS. LC was superior for patients with favorable histologic subtype (P = .046) and SBRT with a higher biological effective dose at isocenter (P = .037), whereas DC was inferior for patients with metastases in multiple organs (P < .001) and female gender (P = .027). Early (within 24 months) local or distant progression was observed in 15.3% and 36.5% of the patients. After 24 months, the risk of late local failure was low, with 3- and 4-year local failure rates of only 4.0%, and 7.6%. In contrast, patients remained at a high risk of distant progression with 3- and 4-year failure rates of 13.3% and 24.1%, respectively, with no plateau observed.CONCLUSION: SBRT for pulmonary oligometastatic NSCLC resulted in favorable LC and promising OS. The dominant failure pattern is distant with a continuously high risk of disease progression for many years.

U2 - 10.1016/j.cllc.2019.06.024

DO - 10.1016/j.cllc.2019.06.024

M3 - SCORING: Journal article

C2 - 31327644

VL - 20

SP - e667-e677

JO - CLIN LUNG CANCER

JF - CLIN LUNG CANCER

SN - 1525-7304

IS - 6

ER -